Cipla: Current AIDS patent pool plan is unrealistic
This article was originally published in Scrip
Executive Summary
The Indian generic company, Cipla, claims that UNITAID's antiretrovirals (ARVs) patent pool proposal will not achieve its goals in its current form, unless country-specific patents are incorporated in the pool and details such as royalty terms and the names of all participating nations are spelt out in "unambiguous" terms.